000 01391 a2200421 4500
005 20250517095743.0
264 0 _c20170524
008 201705s 0 0 eng d
022 _a1464-410X
024 7 _a10.1111/bju.13546
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aChandrapal, Jason C
245 0 0 _aCharacterising the safety of clomiphene citrate in male patients through prostate-specific antigen, haematocrit, and testosterone levels.
_h[electronic resource]
260 _bBJU international
_cDec 2016
300 _a994-1000 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aClomiphene
_xadverse effects
650 0 4 _aEstrogen Antagonists
_xadverse effects
650 0 4 _aHematocrit
650 0 4 _aHumans
650 0 4 _aHypogonadism
_xblood
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aProstate-Specific Antigen
_xblood
650 0 4 _aRetrospective Studies
650 0 4 _aTestosterone
_xblood
650 0 4 _aYoung Adult
700 1 _aNielson, Spencer
700 1 _aPatel, Darshan P
700 1 _aZhang, Chong
700 1 _aPresson, Angela P
700 1 _aBrant, William O
700 1 _aMyers, Jeremy B
700 1 _aHotaling, James M
773 0 _tBJU international
_gvol. 118
_gno. 6
_gp. 994-1000
856 4 0 _uhttps://doi.org/10.1111/bju.13546
_zAvailable from publisher's website
999 _c26060310
_d26060310